Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Thunnissen, E; Weynand, B; Udovicic-Gagula, D; Brcic, L; Szolkowska, M; Hofman, P; Smojver-Ježek, S; Anttila, S; Calabrese, F; Kern, I; Skov, B; Perner, S; Dale, VG; Eri, Z; Haragan, A; Leonte, D; Carvallo, L; Prince, SS; Nicholson, S; Sansano, I; Ryska, A.
Lung cancer biomarker testing: perspective from Europe.
Transl Lung Cancer Res. 2020; 9(3): 887-897. Doi: 10.21037/tlcr.2020.04.07 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Brcic Luka
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future. 2020 Translational Lung Cancer Research. All rights reserved.
Find related publications in this database (Keywords): Lung cancer; predictive testing; therapy; health care; Europe